YZYBIO-B Receives NMPA Acceptance for M701 New Drug Application Targeting Malignant Ascites

Stock News

05/07

YZYBIO-B (02496) has announced that the New Drug Application for its self-developed bispecific antibody drug M701, intended for the treatment of malignant ascites caused by advanced epithelial malignancies, has been formally accepted by the National Medical Products Administration. This acceptance is based on findings from a Phase III clinical trial conducted in China, which evaluated the efficacy and safety of intraperitoneal infusion of M701 in patients with advanced epithelial tumors presenting moderate to large amounts of malignant ascites. The relevant research data is scheduled to be presented at the 2026 American Society of Clinical Oncology annual meeting.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1181865718"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181865718\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181865718?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 17:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181865718","market":"sg","top_or_hot":-1,"title":"YZYBIO-B Receives NMPA Acceptance for M701 New Drug Application Targeting Malignant Ascites","media":"Stock News","content":"<p>YZYBIO-B (02496) has announced that the New Drug Application for its self-developed bispecific antibody drug M701, intended for the treatment of malignant ascites caused by advanced epithelial malignancies, has been formally accepted by the National Medical Products Administration. This acceptance is based on findings from a Phase III clinical trial conducted in China, which evaluated the efficacy and safety of intraperitoneal infusion of M701 in patients with advanced epithelial tumors presenting moderate to large amounts of malignant ascites. The relevant research data is scheduled to be presented at the 2026 American Society of Clinical Oncology annual meeting.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>YZYBIO-B Receives NMPA Acceptance for M701 New Drug Application Targeting Malignant Ascites</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYZYBIO-B Receives NMPA Acceptance for M701 New Drug Application Targeting Malignant Ascites\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-07 17:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>YZYBIO-B (02496) has announced that the New Drug Application for its self-developed bispecific antibody drug M701, intended for the treatment of malignant ascites caused by advanced epithelial malignancies, has been formally accepted by the National Medical Products Administration. This acceptance is based on findings from a Phase III clinical trial conducted in China, which evaluated the efficacy and safety of intraperitoneal infusion of M701 in patients with advanced epithelial tumors presenting moderate to large amounts of malignant ascites. The relevant research data is scheduled to be presented at the 2026 American Society of Clinical Oncology annual meeting.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1181865718","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181865718","pubTimestamp":1778146700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"YZYBIO-B (02496) has announced that the New Drug Application for its self-developed bispecific antibody drug M701, intended for the treatment of malignant ascites caused by advanced epithelial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","IPOS":"Renaissance International IPO ETF","02496":"友芝友生物-B"},"translate_title":"友济生物-B获NMPA受理M701靶向恶性腹水新药申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02496":1,"IPOS":1},"content_text":"YZYBIO-B (02496) has announced that the New Drug Application for its self-developed bispecific antibody drug M701, intended for the treatment of malignant ascites caused by advanced epithelial malignancies, has been formally accepted by the National Medical Products Administration. This acceptance is based on findings from a Phase III clinical trial conducted in China, which evaluated the efficacy and safety of intraperitoneal infusion of M701 in patients with advanced epithelial tumors presenting moderate to large amounts of malignant ascites. The relevant research data is scheduled to be presented at the 2026 American Society of Clinical Oncology annual meeting.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}